Nothing Special   »   [go: up one dir, main page]

DE60325353D1 - Behandlung von mukositis - Google Patents

Behandlung von mukositis

Info

Publication number
DE60325353D1
DE60325353D1 DE60325353T DE60325353T DE60325353D1 DE 60325353 D1 DE60325353 D1 DE 60325353D1 DE 60325353 T DE60325353 T DE 60325353T DE 60325353 T DE60325353 T DE 60325353T DE 60325353 D1 DE60325353 D1 DE 60325353D1
Authority
DE
Germany
Prior art keywords
mucositis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325353T
Other languages
English (en)
Inventor
Robert A Shalwitz
Paul W Johns
Tapas Das
James L Leach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of DE60325353D1 publication Critical patent/DE60325353D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE60325353T 2002-05-21 2003-04-18 Behandlung von mukositis Expired - Lifetime DE60325353D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38222502P 2002-05-21 2002-05-21
PCT/US2003/011840 WO2003099297A1 (en) 2002-05-21 2003-04-18 Treatment of mucositis

Publications (1)

Publication Number Publication Date
DE60325353D1 true DE60325353D1 (de) 2009-01-29

Family

ID=29584378

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325353T Expired - Lifetime DE60325353D1 (de) 2002-05-21 2003-04-18 Behandlung von mukositis

Country Status (9)

Country Link
US (3) US20030236217A1 (de)
EP (1) EP1509234B1 (de)
AR (1) AR040036A1 (de)
AT (1) ATE417616T1 (de)
AU (1) AU2003230952A1 (de)
DE (1) DE60325353D1 (de)
HK (1) HK1074784A1 (de)
TW (1) TW200402301A (de)
WO (1) WO2003099297A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040989A1 (it) * 2004-05-18 2004-08-18 Gentium Spa Uso del sulglicotide per iul trattamento delle mucositi
US20050276762A1 (en) * 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
GB0501476D0 (en) * 2005-01-25 2005-03-02 Heptagen Ltd Treatment for mucositis
WO2009043134A1 (en) 2007-10-03 2009-04-09 Myrex Pharmaceuticals Inc. Mouthwash and method of using same for the treatment of mucositis or stomatitis
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
US20070231274A1 (en) * 2006-03-28 2007-10-04 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
AR058834A1 (es) * 2006-11-06 2008-02-27 Univ Nac Quilmes Un compuesto con actividad inhibitoria de una proteina celular rho-gtpasa, un procedimiento para su obtencion, composiciones farmaceuticas que lo comprenden y un metodo para el tratamiento de una indicacion mediada por una proteina celular rho-gtpasa
US20100305071A1 (en) * 2007-08-30 2010-12-02 Prelief Inc. Methods for improving healing of an oral lesion using a glycerophosphate salt
US7998967B2 (en) 2008-03-03 2011-08-16 Tosk, Incorporated Methotrexate adjuvants to reduce toxicity and methods for using the same
EP3406244B1 (de) 2009-04-15 2023-06-07 BMG Pharma S.p.A. Zusammensetzungen enthaltend zinkgluconat und taurin für schleimhaut- und hautbeschwerden
EP2801348B1 (de) * 2011-12-16 2019-05-22 Hayashibara Co., Ltd. Orale waschzusammensetzung zur vorbeugung und/oder behandlung von periodontopathien
WO2015116860A1 (en) * 2014-01-29 2015-08-06 Vita Ice Therapeutics Llc Edible oil compositions to treat oral complications and methods of using same
US11110112B2 (en) 2016-02-18 2021-09-07 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (ADPR)
ES2949441T3 (es) 2018-03-27 2023-09-28 Invirsa Inc Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR)
CN112789048A (zh) 2018-08-14 2021-05-11 托斯克公司 用于治疗粘膜炎的方法和组合物
MX2021004396A (es) * 2018-10-17 2021-06-04 Lakewood Amedex Inc Metodos y composiciones para el tratamiento de la mucositis oral.
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
KR20230036274A (ko) 2021-09-07 2023-03-14 정근영 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118672A (en) * 1976-07-28 1978-10-03 Nippon Electric Company, Ltd. Attenuation equalizer having constant resistance
US5118672A (en) * 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
JPH07247210A (ja) * 1994-03-09 1995-09-26 Sunstar Inc 口腔用組成物
US5656284A (en) * 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
US5942243A (en) * 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
AU744902B2 (en) * 1997-09-11 2002-03-07 Oxigene, Inc. Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
US6197334B1 (en) * 1998-04-13 2001-03-06 Donald V. Renda Lozenge and method of making
US6624150B2 (en) * 1999-02-26 2003-09-23 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
AU2002246956B2 (en) * 2001-01-04 2006-11-02 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof

Also Published As

Publication number Publication date
HK1074784A1 (en) 2005-11-25
EP1509234B1 (de) 2008-12-17
AU2003230952A1 (en) 2003-12-12
US20060105985A1 (en) 2006-05-18
TW200402301A (en) 2004-02-16
US20030236217A1 (en) 2003-12-25
ATE417616T1 (de) 2009-01-15
WO2003099297A1 (en) 2003-12-04
US20080081796A1 (en) 2008-04-03
EP1509234A1 (de) 2005-03-02
AR040036A1 (es) 2005-03-09

Similar Documents

Publication Publication Date Title
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE60325353D1 (de) Behandlung von mukositis
DE60322582D1 (de) Oberflächenbehandlung von medizinischem gerät
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE50214540D1 (de) Stanz bei der behandlung von wunden
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DE60311298D1 (de) Kopfhautbehandlung
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE602004004262D1 (de) Ultraschallbehandlung von gewebematrices
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE369136T1 (de) Therapeutische behandlung
DE60103685D1 (de) Behandlung von Poriomania
DE602004026773D1 (de) Verfahrensherstellung von ethern
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
DE60026821D1 (de) Behandlung von bohrspülung
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
ATE526970T1 (de) Behandlung von mastitis
DE602004026067D1 (de) Gerät zur Behandlung von Füßen
DE602004004824D1 (de) Automatische Behandlung von Konversationsgruppen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition